Efficacy and Safety of PARP Inhibitors with Hormonal Therapy in Prostate Cancer
Author Information
Author(s): Guo Andong, Wu Chenrui, Cao Jishuang, Zhu Kejia, Ding Sentai
Primary Institution: Shandong Provincial Hospital Affiliated to Shandong First Medical University
Hypothesis
This study evaluated the real-world efficacy and safety of combining PARP inhibitors with novel hormonal therapy as a first-line treatment in mCRPC patients with HRR gene mutations.
Conclusion
Combined first-line treatment with PARP inhibitors and NHT is effective and well-tolerated in mCRPC patients with HRR gene mutations.
Supporting Evidence
- The median PFS for all patients was 21.8 months.
- The overall ORR was 48.8%, and the DCR was 61.0%.
- 81.8% of patients in Cohort A achieved a PSA50 response.
- 85.4% of patients experienced grade 1 or 2 adverse events.
- The Gleason score was identified as a significant predictor of PFS.
Takeaway
Doctors combined two types of cancer treatments to help men with a specific kind of prostate cancer, and it worked well for many of them.
Methodology
This retrospective observational study enrolled 41 mCRPC patients who received combined treatment with PARP inhibitors and NHT, divided into two cohorts based on HRR gene mutations.
Potential Biases
Information bias was possible due to the study's design and small sample size.
Limitations
The study was a single-center real-world study with a small patient cohort, lacking a comparative analysis between combination therapies and PARP inhibitors used alone.
Participant Demographics
The median age was 70 years, with the majority having an ECOG performance status of 0 or 1, and 87.8% had bone metastases.
Statistical Information
P-Value
0.006
Confidence Interval
95% CI: 1.65–20.2
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website